Abstract
BackgroundIndicators of extensive disease—acid fast bacilli (AFB) smear positivity and lung cavitation—have been inconsistently associated with clinical rifampin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) outcomes. We evaluated the association of these indicators with end-of-treatment outcomes.MethodsWe did an individual participant data meta-analysis of people treated for RR/MDR-TB with longer regimens with documented AFB smear and chest radiography findings. We compared people AFB smear-negative without cavities to people: (1) smear-negative with lung cavities; (2) smear-positive without lung cavities and (3) AFB smear-positive with lung cavities. Using multivariable logistic regression accounting for demographic, treatment and clinical factors, we calculated adjusted ORs (aOR) for any unfavourable outcome (death, lost to follow-up, failure/recurrence), and mortality and treatment failure/recurrence alone.ResultsWe included 5596 participants; included participants significantly differed from excluded participants. Overall, 774 (13.8%) were AFB smear-negative without cavities, 647 (11.6%) only had cavities, 1424 (25.4%) were AFB smear-positive alone and 2751 (49.2%) were AFB smear-positive with cavities. The median age was 37 years (IQR: 28–47), 3580 (64%) were male and 686 (12.5%) had HIV. Compared with participants AFB smear-negative without cavities, aOR (95% CI) for any unfavourable outcome was 1.0 (0.8 to 1.4) for participants smear-negative with lung cavities, 1.2 (0.9 to 1.5) if smear-positive without cavities and 1.6 (1.3 to 2.0) if AFB smear-positive with lung cavities. Odds were only significantly increased for mortality (1.5, 95% CI 1.1 to 2.1) and failure/recurrence (2.2, 95% CI 1.5 to 3.3) among participants AFB smear-positive with lung cavities.ConclusionOnly the combination of AFB smear-positivity and lung cavitation was associated with unfavourable outcomes, suggesting they may benefit from stronger regimens.
Funder
McGill University Department of Medicine
McGill University Health Centre Foundation
Subject
Pulmonary and Respiratory Medicine
Reference40 articles.
1. WHO . Global tuberculosis report: 2022. Geneva: World Health Organization; 2022. Available: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
2. WHO . Tuberculosis data repository. Geneva: World Health Organization 2021; Available: https://www.who.int/teams/global-tuberculosis-programme/data [Accessed 12 Sep 2022].
3. Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study;Franke;Am J Respir Crit Care Med,2021
4. Olaru ID , Heyckendorf J , Grossmann S , et al . Time to culture positivity and Sputum smear microscopy during tuberculosis therapy. PLoS One 2014;9:e106075. doi:10.1371/journal.pone.0106075
5. Tuberculosis, Pulmonary Cavitation, and Matrix Metalloproteinases
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献